Clinical trial
Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With…
NCT00382798 · Pharmasset, Industry · Completed
Key facts
| NCT number | NCT00382798 |
|---|---|
| Title | Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and Ribavirin |
| Official title | A Multiple-Center, Observer-Blinded, Randomized, Placebo-Controlled, Single & Multiple Ascending Dose Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, & Food Effect of RO5024048 in Healthy Volunteers & in Patients With Chronic HCV Infection |
| Acronym | R7128 |
| Lead sponsor | Pharmasset, Industry |
| Collaborators | Hoffmann-La Roche Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Healthy Volunteers, Hepatitis C Virus |
| Intervention type | Drug |
| Interventions | RO5024048 |
| Enrollment | 75 |
| Start date | Oct 1, 2006 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Oct 2, 2006 |
| Last update posted | Apr 27, 2009 |
| Countries | New Zealand, Puerto Rico, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: